# PLUVICTO
> **NDA215833** · New Drug Application · Sponsor: NOVARTIS · Approved 2022-03-23
## Drug
- **FDA Application Number:** NDA215833
- **Application type:** New Drug Application
- **Brand name:** PLUVICTO
- **Generic name:** LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN
- **Active ingredients:** LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
- **Dosage form:** SOLUTION
- **Route:** INTRAVENOUS
- **Marketing status:** Prescription
- **Sponsor:** NOVARTIS
- **Manufacturer:** Novartis Pharmaceuticals Corporation
- **First approval:** 2022-03-23
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215833)
---
*MORVS · CC0 1.0*